SunTrust Upgrades Abaxis (ABAX) to Buy
More News related to ABAX
- Abaxis, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
- Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
- Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2010
- Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday, October 27, 2009
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
SunTrust upgrades Abaxis (Nasdaq: ABAX) from Neutral to Buy. Price target $21.
Abaxis, Inc. (Abaxis) develops, manufactures, markets and sells portable blood analysis systems for use in any human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements.
Related Categories
UpgradesStocks Mentioned
+0.75Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
